deltatrials
Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT04455841

INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

Sponsor: Incyte Corporation

Conditions Anemia Post-essential Thrombocythemia Myelofibrosis Post-polycythemia Vera Myelofibrosis
Interventions INCB000928 ruxolitinib
Updated 32 times since 2020 Last updated: Dec 22, 2025 Started: Mar 19, 2021 Primary completion: Apr 1, 2025 Completion: Nov 26, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Anemia and Post-essential Thrombocythemia Myelofibrosis, this trial is ongoing. The trial is conducted by Incyte Corporation and has accumulated 32 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Aug 2020 – ~Oct 2020 · 2 months · monthly snapshot~Oct 2020 – ~Dec 2020 · 2 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Apr 2021 · 59 days · monthly snapshot~Apr 2021 – ~Oct 2021 · 6 months · monthly snapshot~Oct 2021 – ~Mar 2022 · 5 months · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jun 2023 · 6 months · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Sep 2023 · 2 months · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Mar 2024 · 2 months · monthly snapshot~Mar 2024 – ~Apr 2024 · 31 days · monthly snapshot~Apr 2024 – ~May 2024 · 30 days · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Jan 2025 · 2 months · monthly snapshot~Jan 2025 – ~Jun 2025 · 5 months · monthly snapshot~Jun 2025 – ~Aug 2025 · 2 months · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – ~Jan 2026 · 4 months · monthly snapshot~Jan 2026 – present · 7 months · monthly snapshot

Change History

32 versions recorded

  1. Jan 2026 — Present [monthly]

    Active Not Recruiting PHASE1/PHASE2

  2. Sep 2025 — Jan 2026 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  3. Aug 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  4. Jun 2025 — Aug 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  5. Jan 2025 — Jun 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Status: Recruiting → Active Not Recruiting

▶ Show 27 earlier versions

  1. Nov 2024 — Jan 2025 [monthly]

    Recruiting PHASE1/PHASE2

  2. Sep 2024 — Nov 2024 [monthly]

    Recruiting PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. May 2024 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

  5. Apr 2024 — May 2024 [monthly]

    Recruiting PHASE1_PHASE2

  6. Mar 2024 — Apr 2024 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jan 2024 — Mar 2024 [monthly]

    Recruiting PHASE1_PHASE2

  8. Dec 2023 — Jan 2024 [monthly]

    Recruiting PHASE1_PHASE2

  9. Nov 2023 — Dec 2023 [monthly]

    Recruiting PHASE1_PHASE2

  10. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE1_PHASE2

  11. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE1_PHASE2

  12. Jul 2023 — Sep 2023 [monthly]

    Recruiting PHASE1_PHASE2

  13. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE1_PHASE2

  14. Dec 2022 — Jun 2023 [monthly]

    Recruiting PHASE1_PHASE2

  15. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE1_PHASE2

  16. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE1_PHASE2

  17. Jun 2022 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  18. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE1_PHASE2

  19. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE1_PHASE2

  20. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE1_PHASE2

  21. Oct 2021 — Mar 2022 [monthly]

    Recruiting PHASE1_PHASE2

  22. Apr 2021 — Oct 2021 [monthly]

    Recruiting PHASE1_PHASE2

  23. Feb 2021 — Apr 2021 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  24. Jan 2021 — Feb 2021 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  25. Dec 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  26. Oct 2020 — Dec 2020 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  27. Aug 2020 — Oct 2020 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Incyte Corporation
Data source: Incyte Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Angers, France , Atlanta, United States , Bergamo, Italy , Bologna, Italy , Boston, United Kingdom , Bunkyō City, Japan , Cardiff, United Kingdom , Chiba, Japan , Duarte, United States , Durham, United States and 23 more locations